Xeris Pharmaceuticals (XERS) intends to raise $75 million in an IPO of its common stock on the Nasdaq Exchange. The company is developing a variety of injectable and continuous treatments for diabetic conditions. XERS has had apparent Phase 3 trial success and is planning to ramp up commercialization efforts for the latter half of 2019. [Seeking Alpha: Xeris Pharmaceuticals (XERS)]
Stay updated on Xeris Pharmaceuticals (XERS) as we continue to follow their journey through the IPO!
Xeris Pharmaceuticals: https://www.xerispharma.com/